Delayed administration of a matrix metalloproteinase inhibitor limits progressive brain injury after hypoxia-ischemia in the neonatal rat

Pharmacology, Toxicology and Pharmaceutical Science

• Brain Injury 100%
• Ischemia 100%
• Hypoxia 100%
• Matrix Metalloproteinase Inhibitor 100%
• Prinomastat 100%
• Rat 100%
• Minocycline 80%
• Astrocytosis 60%
• Anti-Inflammatory Drug 40%
• Injury 40%
• Nervous System Inflammation 40%
• Nervous System Injury 40%
• Gelatinase A 40%
• Gelatinase B 40%
• Matrix Metalloproteinase 40%
• Animal 20%
• Sprague Dawley Rat 20%
• Reactive Oxygen Metabolite 20%
• Gelatinase Inhibitor 20%
• Cytokine 20%
• Proteinase 20%
• Nerve Degeneration 20%
• Chemokine 20%
• Gelatinase 20%
• Neuropathy 20%
• White Matter Injury 20%
• Gelatin 20%
• Neuroprotective Agent 20%
• Glial Fibrillary Acidic Protein 20%

Neuroscience

• Brain Injury 100%
• Prinomastat 100%
• Ischemia 100%
• Matrix Metalloproteinase Inhibitor 100%
• Minocycline 80%
• Astrogliosis 60%
• Microglia 60%
• Anti-Inflammatory 40%
• MMP9 40%
• Staining Technique 40%
• MMP2 40%
• Macrophage 40%
• Matrix Metalloproteinase 40%
• Gelatinase 40%
• Extracellular Matrix 40%
• Striatum 20%
• Reactive Oxygen Species 20%
• Neuroprotective Agent 20%
• Hippocampus 20%
• Proteolysis 20%
• White Matter 20%
• Glial Fibrillary Acidic Protein 20%
• Parietal Cortex 20%
• Selectivity 20%
• Leukocyte 20%
• Proteinase 20%
• Cell Activation 20%
• Gelatin 20%
• Neurodegeneration 20%
• Immunohistochemistry 20%
• Chemokine 20%
• Neuropathy 20%